StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Premarin Family [legacy through FY24] by Quarter

Premarin Family (conjugated estrogens) [legacy through FY24] — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Premarin Family [legacy through FY24]: $86M in Q4 2024, down 2.3% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2024
86
Period ended Dec 31, 2024
Change on a year earlier
-2.3%
88 in Q4 2023
History
32 quarters
Since Q4 2016
Sources
28
Documents cited below

Where the Q4 2024 figure comes from

“|| Premarin family | 97 | 98 | (1%) | (1%) | 86 | 88 | (3%) | 11 | 10 | 14% | 12%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPremarin Family (conjugated estrogens) [legacy through FY24] — U.S. revenues ($M) ($M)Year on yearSource
Q4 2024Dec 31, 202486-2.3%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 202480-3.6%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 202498+14.0%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q4 2023Dec 31, 202388-26.1%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 202383-17.0%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 202386-18.9%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023104+10.6%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 2022119-11.9%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 2022100-28.1%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2022Jul 3, 2022106-10.2%Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2022Apr 3, 202294-29.3%Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2021Dec 31, 2021135-31.5%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2021Oct 3, 2021139-11.5%Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2021Jul 4, 2021118-16.9%Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2021Apr 4, 2021133-5.7%Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2020Dec 31, 2020197+3,183.3%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗

Breakdown

What makes up premarin Family [legacy through FY24]

Cite this data

StockData. (2026). Pfizer Premarin Family [legacy through FY24] ($M), quarterly Q4 2016–Q4 2024 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/premarin-leg-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.